Table 2.

Summary of eptinezumab RCTs

Study	Phase	Migraine/N	Study period	Primary outcome
NCT01772524 Dodick et al. (2014) [23]	II	EM N = 174	3 months	placebo: −4.6 1000 mg: − 5.6 (p = 0.03)
NCT02275117 Dodick et al. (2019) [24]	II	CM N = 616	3 months	≥ 75% migraine responder rate: placebo: 20.7% 10 mg: 33.3% (p = 0.033) 30 mg, 100 mg, 1000 mg (all NS)
NCT02559895 Ashina et al. (2020) (PROMISE-1) [25]	III	EM N = 888	3 months	placebo: −3.2 30 mg: − 4.0 (p = 0.0046) 100 mg: −3.9 (p = 0.0182) 300 mg: − 4.3 (p = 0.0001)
NCT02974153 Lipton et al. (2020) (PROMISE-2) [26]	III	CM N = 1072	12 weeks	placebo: −5.6 100 mg: −7.7 (p < 0.0001) 300 mg: −8.2 (p < 0.0001)
NCT04152083 Winner et al. (2021) (RELIEF) [27]	III	CM N = 480	Acute treatment	Time to pain freedom: placebo: 9 h 100 mg: 4 h (p < 0.001) Time to absence of MBS: placebo: 3 h 100 mg: 2 h (p < 0.001)

All eptinezumab treatments were given intravenously. Primary outcome was MMD reduction for all studies except RELIEF and Dodick (2019) [24]

EM episodic migraine, CM chronic migraine, MMD mean monthly migraine day, NS non-significant